Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Erythropoietin for Alveolar Ridge Preservation
NCT06513039Phase 4Recruiting
- Sponsor
- Ain Shams University
- Start
- Jan 2024
- Primary completion
- Jan 2025
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of erythropoietin in Alveolar bone loss (3 arms), sponsored by Ain Shams University. Primary endpoints: Dimensional changes width changes at 4 months and Radiographic Dimensional changes at 4 months. Started Jan 2024; status: recruiting.
02
Drugs
erythropoietin
03
Conditions
Alveolar bone loss
Beyond the preview
Go deeper on NCT06513039.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06513039.